Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 222

The DOI matches its Crossref record.

Failure of a motilin receptor agonist (ABT‐229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double‐blind placebo‐controlled trial

Talley, N. J., Verlinden, M., Snape, W., Beker, J. A., Ducrotte, P., Dettmer, A., Brinkhoff, H., Eaker, E., Ohning, G., Miner, P. B, Mathias, J. R, Fumagalli, I., Staessen, D., Mack, R. J.·2000·Alimentary Pharmacology & Therapeutics

Abstract

Introduction: Motilin‐receptor agonists are prokinetics; whether they relieve the symptoms of functional dyspepsia is unknown. We aimed to test the efficacy of the motilin agonist ABT‐229 in functional dyspepsia patients with and without delayed gastric emptying. Methods: Patients were randomized with postprandial symptoms and documented functional dyspepsia by endoscopy (n=589 in intention‐to‐treat analysis). Patients were assigned to either the delayed or normal gastric emptying strata, based on a validated 13 C octanoic acid breath test. Patients were then further randomized within each strata, to receive one of four doses of ABT‐229 (1.25, 2.5, 5 or 10 mg b.d. before breakfast and dinner) or placebo for 4 weeks, following a 2‐week baseline. The primary outcome was the assessment of change in symptom severity over the 2 weeks from baseline to final visit, based on a self‐report questionnaire measuring severity on visual analogue scales. Results: Baseline characteristics across the treatment arms were very similar. No significant differences in the upper abdominal discomfort severity score (maximum 800 mm) were observed for any active treatment arm vs. placebo (mean change from baseline −139, −141, −145, −160 and −134 mm for placebo, 1.25, 2.5, 5, and 10 mg, respectively, at 4 weeks by intention‐to‐treat). More patients on placebo reported a good or excellent global response than patients on 1.25 or 5 mg of active therapy (both P < 0.05). The results were very similar in those with and without delayed gastric emptying. Helicobacter pylori status did not predict response. Excluding patients with any baseline heartburn (total remaining n=240), ABT‐229 10 mg was inferior to placebo in relief of upper abdominal discomfort. Conclusions: ABT‐229 was of no value for relief of symptoms in functional dyspepsia, compared with placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2000.00868.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 222

Metadata

Authors
Talley, N. J., Verlinden, M., Snape, W., Beker, J. A., Ducrotte, P., Dettmer, A., Brinkhoff, H., Eaker, E., Ohning, G., Miner, P. B., Mathias, J. R., Fumagalli, I., Staessen, D., & Mack, R. J.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2000-12-27
Volume
14
Issue
12
Pages
1653-1661
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1977331693
Cited by
222
References
0
FWCI
10.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Failure of a motilin receptor agonist (ABT‐229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double‐blind placebo‐controlled trial. https://app.cochat.ai/papers/10.1046/j.1365-2036.2000.00868.x
The paper
Talley, N. J., Verlinden, M., Snape, W., Beker, J. A., Ducrotte, P., Dettmer, A., Brinkhoff, H., Eaker, E., Ohning, G., Miner, P. B., Mathias, J. R., Fumagalli, I., Staessen, D., & Mack, R. J. (2000). Failure of a motilin receptor agonist (ABT‐229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double‐blind placebo‐controlled trial. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2000.00868.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.